ExeVir
Caroline Sagaert has a wealth of experience in the pharmaceutical industry, holding various leadership positions at companies like ExeVir, CAGISA Consulting, GSK, Innogenetics, and UCB. Caroline is currently the Founder and Owner of CAGISA Consulting, a vaccine and pharma consultancy focusing on Target Product Profile. With a background in business development, market research, and commercial strategy, Caroline has demonstrated expertise in shaping early value evidence and global value strategy. Caroline holds a degree in CEPAC from Solvay Brussels School of Economics and Management and completed the Global Leadership Programme at UCB.
ExeVir
Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.